Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2020-07-22 Capital/Financing Update
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a one-year extension of the maturity date of a debenture, including details about the terms of the extension and warrants issued. It focuses on financing activity related to the company's debt instruments. There are no financial statements or comprehensive financial data presented, nor is it an announcement of a report publication. The content clearly relates to capital structure and financing updates. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 4082 characters, which is consistent with a typical announcement rather than a full report.
2020-07-22 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Resverlogix has reached an agreement with the FDA regarding the clinical plan for a drug registration enabling study (BETonMACE2). It discusses regulatory interactions, clinical trial design, and future development plans, but does not contain financial statements, earnings data, or detailed financial analysis. It is not a full annual or interim report, nor is it a transcript, audit, or governance document. The content focuses on regulatory and clinical development updates, which are typical of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like earnings release or capital update. The document length is 8362 characters, which is substantial but the content is clearly an announcement rather than a full report. Therefore, the best classification is Regulatory Filings (RNS).
2020-06-22 English
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a press release announcing a corporate update conference call and webcast scheduled for June 10, 2020, and an upcoming presentation at a virtual congress on June 9, 2020. It provides details on how to join the call and webcast, including dial-in numbers and webcast links. The document does not contain any financial statements, detailed financial analysis, or substantive financial data. It is primarily an announcement of an event where the company will provide updates, rather than the update itself. The document length is 5164 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Investor Presentation (IP) as it is about a corporate update presentation event for investors and interested parties.
2020-06-06 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document text contains only a placeholder message indicating that the PDF viewer cannot display the document content. There is no substantive content related to any financial report, announcement, or filing. It does not contain any financial data, regulatory references, or report titles. Therefore, it cannot be classified as any specific filing type and falls under the fallback category for miscellaneous or non-informative filings.
2020-05-07 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document text contains only a placeholder message indicating that the PDF viewer cannot display the document content. There is no substantive content related to any financial report, announcement, or filing. The text is very short (692 characters) and does not contain any keywords or references to filings, reports, or regulatory bodies. Therefore, it does not fit any specific filing category and should be classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit elsewhere.
2020-03-27 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a recent scientific publication related to the company's clinical candidate apabetalone as a potential COVID-19 treatment. It contains no financial data, no regulatory form references, no meeting or voting information, no management or board changes, no earnings or interim report data, and no detailed financial or governance disclosures. The content is primarily promotional and informational about a scientific publication and the company's drug development efforts. It does not fit into any specific financial or regulatory report category. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other categories.
2020-03-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.